BCL2L1 and acute myeloid leukemia: Multiple mechanisms including dependency on alternative anti-apoptotic proteins Bcl-xL or Mcl-1 contribute to venetoclax resistance [12], supporting that co-targeting more than one cell survival mechanisms is needed to improve the efficacy of venetoclax in AML [13].